Blemish
Benzoyl Peroxide
Kamins Dermatologics Inc.
Human Otc Drug
NDC 63550-193Blemish also known as Benzoyl Peroxide is a human otc drug labeled by 'Kamins Dermatologics Inc.'. National Drug Code (NDC) number for Blemish is 63550-193. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Blemish drug includes Benzoyl Peroxide - 50 mg/mL . The currest status of Blemish drug is Active.
Drug Information:
| Drug NDC: | 63550-193 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Blemish |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Benzoyl Peroxide |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Kamins Dermatologics Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Gel |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | BENZOYL PEROXIDE - 50 mg/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | TOPICAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Oct, 2010 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 24 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part333D |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Kamins Dermatologics Inc.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 308694
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | W9WZN9A0GM
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 63550-193-23 | 30 mL in 1 BOX (63550-193-23) | 01 Oct, 2010 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose: acne treatment
Product Elements:
Blemish benzoyl peroxide water acer saccharum sap dimethicone sodium hydroxide phenoxyethanol caprylyl glycol sorbic acid benzoyl peroxide benzoyl peroxide
Indications and Usage:
A unique oil-free, color-free benzoyl peroxide gel that helps to gently clear blemishes, blackheads and spots. also contains our moisturizing bio-maple compound, which helps prevent skin from becoming excessively dry. uses â helps treat acne. â dries up acne pimples. â helps prevent new acne pimples.
Warnings:
Warnings for external use only. do not use on broken skin. large areas of the body. when using this product, apply to affected areas only avoid unnecessary sun exposure and use a sunscreen avoid contact with eyes/eye area, lips, mouth and nostrils. if contact occurs, rinse thoroughly with water. this product may bleach hair or dyed fabrics. using other topical acne drugs at the same time or right after use of this product may increase dryness or irritation of the skin. only one drug should be used unless directed by a doctor. stop use and ask a doctor if too much skin irritation or sensitivity develops or increases. if swallowed, seek medical assistance or contact a poison control center immediately.
Dosage and Administration:
Directions clean the skin thoroughly befor applying. cover the entire affected area with a thin layer 1 to 3 times daily. because too much drying of the skin may occur, start with 1 application daily, then gradually increase to 2-3 times daily if needed or as directed by a doctor. if bothersome dryness or peeling occurs, reduce application to once a day or every other day. if going outside, use a sunscreen. allow medicated acne gel to dry, then follow directions on the sunscreen labeling.
Package Label Principal Display Panel:
B. kamins blemish gel 5% 30ml / 1.7 fl.oz din 02248217 blemish front panel image